story of the week
Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Monotherapy vs Placebo in Patients With Resected Stage IV Melanoma With No Evidence of Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Monotherapy Versus Placebo in Patients With Resected Stage IV Melanoma With No Evidence of Disease (IMMUNED): A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
Lancet 2020 May 16;395(10236)1558-1568, L Zimmer, E Livingstone, JC Hassel, M Fluck, T Eigentler, C Loquai, S Haferkamp, R Gutzmer, F Meier, P Mohr, A Hauschild, B Schilling, C Menzer, F Kieker, E Dippel, A Rösch, JC Simon, B Conrad, S Körner, C Windemuth-Kieselbach, L Schwarz, C Garbe, JC Becker, D Schadendorf,From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.